Press Releases

SUZHOU, China and ROCKVILLE, Md., Nov. 20, 2019 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies, announced that the groundbreaking ceremony for the Company’s global headquarters, R&D center, and manufacturing facility took place today at the Suzhou Industrial Park (SIP). The ceremony marks another milestone in Ascentage Pharma’s path of developing innovative therapies. Read More ›

SUZHOU, China and ROCKVILLE, MD., November 14, 2019 — Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the updated preliminary results from a Phase I clinical trial on the company’s novel investigational drug HQP1351 has been accepted for oral Read More ›

SUZHOU, China and ROCKVILLE, Md., November 4, 2019 —  Ascentage Pharma（6855.HK）, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced a combination therapy strategic collaboration with Henlius (2696.HK), working together to conduct clinical trials of the combination therapy between APG-2575, a novel, orally administered Bcl-2 selective inhibitor developed by Read More ›

Oct 28, 2019, is an unforgettable day for every employee working at Ascentage Pharma. A new history was made when the bell rang at 9:30 a.m. Marking a major milestone in the history of Ascentage, the company was officially listed on the Hong Kong Stock Exchange after the 10-year journey of persistent innovation. For those Read More ›

SUZHOU, China and ROCKVILLE, Md., July 21, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company was notified by the U.S. Food & Drug Administration (FDA) on the clearance of the Investigational New Drug (IND) application which allows the company to initiate Read More ›

SUZHOU, China and ROCKVILLE, Md., July 14, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company recently dosed the first patient successfully in a Phase I clinical trial of APG-2575, a novel Bcl-2 selective inhibitor, for the treatment of hematologic malignancies in China. The Read More ›

SUZHOU, China and Chicago, June 3, 2019 — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced that the company presented new data of two apoptosis-targeted drug candidates APG-115 (a novel MDM2-p53 inhibitor) and APG-1387 (a novel IAP inhibitor) at the 55th Read More ›

SUZHOU, China and HONG KONG and ROCKVILLE, Md., May 22, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced the presentation of new clinical data for its investigational apoptosis-targeted drug candidates at the 55th Annual Meeting of the American Read More ›

ROCKVILLE, M.D. and HONG KONG, April 8, 2019 /PRNewswire/ — Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B and age-related diseases, today announced that it has entered into a strategic collaboration with Shanghai Junshi Biosciences Co., Ltd. to explore the synergies of Ascentage’s Inhibitor of Apoptosis Proteins Read More ›

ROCKVILLE, MD and HONG KONG, CHINA— March 26th, 2019—Ascentage Pharma, globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases s, today announced that research results of its pipeline of small molecule therapeutics will be presented at the 2019 American Association for Cancer Research (AACR) annual meeting in Atlanta, Read More ›